About SUPPRELIN® LA -
Estradiol Suppresion

Estradiol levels remained suppressed through the third year of therapy1

SUPPRELIN® LA allows you to start and stop the delivery of medication quickly with a minor surgical procedure2

In a phase 3 study...3

  • After 1 month of implantation, suppression of LH was induced in all treatment-naive subjects and maintained in all pretreated subjects
  • After 1 month of removal, LH values in the four subjects in whom it was decided to allow puberty to ensue ranged from 6.7 to 16 mIU/ml at month 13, and histrelin levels were undetectable -- demonstrating that the suppression obtained with SUPPRELIN LA was completely reversible (n=4)

Reference:
1. Data on file, DOF-SP-01. Endo Pharmaceuticals; 2009.
2. SUPPRELIN® LA [package insert]. Chadds Ford, PA: Endo Pharmaceuticals Solutions Inc; 2011.
3. Eugster EA, Clarke W, Kletter GB, et al. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. J Clin Endocrinol Metab. 2007;92(5):1697-1704.

Next: SUPPRELIN® LA Rate of Bone Maturation


Indication

SUPPRELIN® LA (histrelin acetate) subcutaneous implant is used for the treatment of children with central precocious puberty (CPP).

Important Safety Information

  • SUPPRELIN LA should not be used by women who are or may become pregnant, and in patients who are allergic to gonadotropin releasing hormone (GnRH) or GnRH agonist analogs. Safety and effectiveness in children under 2 years of age has not been determined.

  • SUPPRELIN LA, like other GnRH agonists, may cause a temporary increase in the blood levels of specific hormones associated with the onset of puberty (estrogen in girls and testosterone in both sexes) during the first week of treatment. This increase may temporarily worsen puberty symptoms during the first week, additionally, you may see new symptoms appear during this period. Within the 4 weeks of treatment with SUPPRELIN LA, hormonal suppression generally occurs and the physical signs of puberty should decrease.

  • Your doctor should monitor the levels of specific hormones associated with puberty progression, 1 month after starting SUPPRELIN LA and then every 6 months thereafter. Every 6-12 months, height and bone age should be also monitored by your doctor.

  • During the clinical trial testing of SUPPRELIN LA, the most common side effects involved the implant site and included temporary bruising, pain, soreness, redness of the skin and swelling.

Please talk with your doctor for more information or if you have any questions.